Mizuho Issues Pessimistic Forecast for Ardent Health (NYSE:ARDT) Stock Price

Ardent Health (NYSE:ARDT) had its target price decreased by analysts at Mizuho from $20.00 to $12.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price objective would indicate a potential upside of 34.00% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Ardent Health in a research note on Monday. Stephens lowered their price target on Ardent Health from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Friday, November 14th. Bank of America decreased their target price on Ardent Health from $12.00 to $10.00 and set an “underperform” rating for the company in a research note on Thursday, November 13th. Leerink Partners set a $16.00 price target on Ardent Health in a research report on Friday, November 14th. Finally, KeyCorp cut Ardent Health from an “overweight” rating to a “sector weight” rating in a research report on Monday, November 17th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $14.92.

Ardent Health Stock Performance

ARDT opened at $8.96 on Thursday. The company has a market cap of $1.28 billion, a PE ratio of 6.18, a price-to-earnings-growth ratio of 7.35 and a beta of 0.77. The stock has a 50-day moving average of $11.70 and a 200-day moving average of $12.45. Ardent Health has a 52-week low of $8.28 and a 52-week high of $17.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.95 and a current ratio of 2.08.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Ardent Health had a return on equity of 19.02% and a net margin of 3.24%.The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. As a group, equities research analysts forecast that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ARDT. Vanguard Group Inc. boosted its stake in Ardent Health by 368.9% during the first quarter. Vanguard Group Inc. now owns 1,330,635 shares of the company’s stock worth $18,296,000 after buying an additional 1,046,845 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Ardent Health by 100.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 57,255 shares of the company’s stock valued at $787,000 after acquiring an additional 28,650 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Ardent Health by 140.1% during the 1st quarter. Deutsche Bank AG now owns 6,882 shares of the company’s stock valued at $95,000 after acquiring an additional 4,016 shares in the last quarter. Invesco Ltd. bought a new stake in Ardent Health in the first quarter valued at about $226,000. Finally, Nuveen LLC bought a new position in Ardent Health during the first quarter worth about $6,010,000.

Ardent Health Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.